The Rockwell Experience Center will teach ARMI members how to increase delivery speeds by leveraging smart manufacturing in the scaling of regenerative medicine products.
Rockwell Automation announced the grand opening of the Rockwell Experience Center at the Advanced Regenerative Manufacturing Institute (ARMI), in Manchester, N.H. on June 8, 2022. The Rockwell Experience Center is designed to teach its ARMI members how to increase delivery speeds by leveraging smart manufacturing in the scaling of regenerative medicine products. ARMI is a member-based, nonprofit organization whose goal is to advance the bioeconomy of the United States.
According to a company press release, the focal point of the center is a fully automated Cytiva equipment process train that is integrated with various Rockwell technologies, including a distributed control system, a manufacturing execution system, and a digital twin. The center also contains equipment from Air Science, Fester, and HID Global.
“To say that the addition of the Rockwell Experience Center at the ARMI|BioFabUSA facility will be impactful to the area of regenerative medicine would be an understatement,” said Dean Kamen, executive director of ARMI, in the press release. “By opening this center, we are able to demonstrate the baseline tools by which different types of human tissues and organs can be manufactured at scale. It's life-changing.”
“The Rockwell Experience Center demonstrates Rockwell’s long-standing support of ARMI and the role smart manufacturing technologies can play to bring regenerative medicine to scale,” said Blake Moret, ARMI board member and chairman, and CEO, Rockwell Automation, in the press release. “ARMI’s work training workers to compete and win in this fast-moving industry is an exciting model for manufacturing and for American competitiveness.”
Source: Rockwell Automation
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.